Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
160.00
+10.50 (7.02%)
At close: Feb 11, 2026

TPE:6919 Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-488.25-588.83-488.46-286.16-224.29-98.49
Depreciation & Amortization
30.2829.5127.8725.3423.2818.21
Loss (Gain) From Sale of Assets
---0.11--
Stock-Based Compensation
118.0565.0522.9819.7174.768.28
Other Operating Activities
-36.38-6.69-0.35-0.36-3.270.86
Change in Accounts Receivable
9.82.71-4.77-3.12-3.2
Change in Inventory
-2.11-1.841.78-2.762.48-2.51
Change in Accounts Payable
-3.23-0.73-0.832.21-0.41-0.3
Change in Unearned Revenue
1.732.59-3.474.5--
Change in Other Net Operating Assets
-36.8-24.0821.32-2.2216.7723.51
Operating Cash Flow
-406.91-522.31-423.94-242.76-110.7-47.24
Capital Expenditures
-12.91-10-8.6-14.16-14.9-2.31
Sale of Property, Plant & Equipment
---0--
Sale (Purchase) of Intangibles
-0.61-1.09-1.09---
Investment in Securities
-5,606-2,478166.78-456.18--
Other Investing Activities
-4.41-0.01-0.2--
Investing Cash Flow
-5,624-2,489157.09-470.54-14.9-2.31
Long-Term Debt Issued
-----8.13
Total Debt Issued
-----8.13
Short-Term Debt Repaid
------5
Long-Term Debt Repaid
--8.58-8.22-12.6-93.98-27.83
Total Debt Repaid
-8.83-8.58-8.22-12.6-93.98-32.83
Net Debt Issued (Repaid)
-8.83-8.58-8.22-12.6-93.98-24.7
Issuance of Common Stock
64.086,4993,042784.32720.88147.43
Repurchase of Common Stock
-----0.09-
Other Financing Activities
-23.480.52----
Financing Cash Flow
31.776,4913,034771.72626.81122.74
Foreign Exchange Rate Adjustments
-25.99-0.110.321.730.14-1.32
Net Cash Flow
-6,0253,4792,76760.15501.3571.87
Free Cash Flow
-419.82-532.31-432.54-256.93-125.6-49.55
Free Cash Flow Margin
-1199.83%-1197.97%-1111.01%-2004.12%-1017.90%-478.70%
Free Cash Flow Per Share
-0.27-0.37-0.35-0.22-0.14-0.07
Cash Interest Paid
0.20.330.50.676.183.65
Cash Income Tax Paid
----0.030.09
Levered Free Cash Flow
-375.46-391.26-266.4-171.06-74-19.88
Unlevered Free Cash Flow
-375.33-391.05-266.09-170.65-72.19-17.06
Change in Working Capital
-30.61-21.3514.03-1.418.8423.9
Source: S&P Global Market Intelligence. Standard template. Financial Sources.